Last reviewed · How we verify
pSG2.HIVconsv DNA vaccine
pSG2.HIVconsv DNA vaccine is a Biologic drug developed by University College, London. It is currently in Phase 1 development.
At a glance
| Generic name | pSG2.HIVconsv DNA vaccine |
|---|---|
| Sponsor | University College, London |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination (PHASE1, PHASE2)
- Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults (PHASE1, PHASE2)
- Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pSG2.HIVconsv DNA vaccine CI brief — competitive landscape report
- pSG2.HIVconsv DNA vaccine updates RSS · CI watch RSS
- University College, London portfolio CI
Frequently asked questions about pSG2.HIVconsv DNA vaccine
What is pSG2.HIVconsv DNA vaccine?
pSG2.HIVconsv DNA vaccine is a Biologic drug developed by University College, London.
Who makes pSG2.HIVconsv DNA vaccine?
pSG2.HIVconsv DNA vaccine is developed by University College, London (see full University College, London pipeline at /company/university-college-london).
What development phase is pSG2.HIVconsv DNA vaccine in?
pSG2.HIVconsv DNA vaccine is in Phase 1.
Related
- Manufacturer: University College, London — full pipeline
- Compare: pSG2.HIVconsv DNA vaccine vs similar drugs
- Pricing: pSG2.HIVconsv DNA vaccine cost, discount & access